235 related articles for article (PubMed ID: 19384912)
1. Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease.
Lamb CA; Mohiuddin MK; Gicquel J; Neely D; Bergin FG; Hanson JM; Mansfield JC
Br J Surg; 2009 Jun; 96(6):663-74. PubMed ID: 19384912
[TBL] [Abstract][Full Text] [Related]
2. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn's disease.
Scarpa M; D'Incà R; Basso D; Ruffolo C; Polese L; Bertin E; Luise A; Frego M; Plebani M; Sturniolo GC; D'Amico DF; Angriman I
Dis Colon Rectum; 2007 Jun; 50(6):861-9. PubMed ID: 17473939
[TBL] [Abstract][Full Text] [Related]
3. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.
Sipponen T; Kärkkäinen P; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Aliment Pharmacol Ther; 2008 Nov; 28(10):1221-9. PubMed ID: 18752630
[TBL] [Abstract][Full Text] [Related]
4. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment.
Sipponen T; Björkesten CG; Färkkilä M; Nuutinen H; Savilahti E; Kolho KL
Scand J Gastroenterol; 2010 Mar; 45(3):325-31. PubMed ID: 20034360
[TBL] [Abstract][Full Text] [Related]
5. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
[TBL] [Abstract][Full Text] [Related]
6. Faecal calprotectin in the assessment of Crohn's disease activity.
Gaya DR; Lyon TD; Duncan A; Neilly JB; Han S; Howell J; Liddell C; Stanley AJ; Morris AJ; Mackenzie JF
QJM; 2005 Jun; 98(6):435-41. PubMed ID: 15879440
[TBL] [Abstract][Full Text] [Related]
7. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers.
Joshi S; Lewis SJ; Creanor S; Ayling RM
Ann Clin Biochem; 2010 May; 47(Pt 3):259-63. PubMed ID: 19740914
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
10. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study.
Kallel L; Ayadi I; Matri S; Fekih M; Mahmoud NB; Feki M; Karoui S; Zouari B; Boubaker J; Kaabachi N; Filali A
Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):340-5. PubMed ID: 19581809
[TBL] [Abstract][Full Text] [Related]
11. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
12. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease.
Jones J; Loftus EV; Panaccione R; Chen LS; Peterson S; McConnell J; Baudhuin L; Hanson K; Feagan BG; Harmsen SW; Zinsmeister AR; Helou E; Sandborn WJ
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1218-24. PubMed ID: 18799360
[TBL] [Abstract][Full Text] [Related]
13. Fecal calprotectin and lactoferrin as noninvasive markers of pediatric inflammatory bowel disease.
Joishy M; Davies I; Ahmed M; Wassel J; Davies K; Sayers A; Jenkins H
J Pediatr Gastroenterol Nutr; 2009 Jan; 48(1):48-54. PubMed ID: 19172123
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
[TBL] [Abstract][Full Text] [Related]
15. Faecal calprotectin: a new marker for Crohn's disease?
Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
[TBL] [Abstract][Full Text] [Related]
16. A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease.
Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
Aliment Pharmacol Ther; 2013 Mar; 37(6):613-21. PubMed ID: 23347334
[TBL] [Abstract][Full Text] [Related]
17. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M
Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984
[TBL] [Abstract][Full Text] [Related]
18. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery.
Wright EK; Kamm MA; De Cruz P; Hamilton AL; Ritchie KJ; Krejany EO; Leach S; Gorelik A; Liew D; Prideaux L; Lawrance IC; Andrews JM; Bampton PA; Jakobovits SL; Florin TH; Gibson PR; Debinski H; Macrae FA; Samuel D; Kronborg I; Radford-Smith G; Selby W; Johnston MJ; Woods R; Elliott PR; Bell SJ; Brown SJ; Connell WR; Day AS; Desmond PV; Gearry RB
Gastroenterology; 2015 May; 148(5):938-947.e1. PubMed ID: 25620670
[TBL] [Abstract][Full Text] [Related]
19. Correlation Between Calprotectin and Modified Rutgeerts Score.
Lopes S; Andrade P; Afonso J; Rodrigues-Pinto E; Dias CC; Macedo G; Magro F
Inflamm Bowel Dis; 2016 Sep; 22(9):2173-81. PubMed ID: 27482974
[TBL] [Abstract][Full Text] [Related]
20. Faecal lactoferrin, capsule endoscopy and Crohn's disease. Is there a three way relationship? A pilot study.
Sidhu R; Sanders DS; Wilson P; Foye L; Morley S; McAlindon ME
J Gastrointestin Liver Dis; 2010 Sep; 19(3):257-60. PubMed ID: 20922188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
